Attention Deficit Hyperactivity Disorder
📧 Sign up to get email alerts when something new happens for Attention Deficit Hyperactivity Disorder.
Sign up freeTop drugs studied for this disease
-
FDA approval · 2015-04-17FDA Approved: DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE — Supplemental Application (Epic Pharma, LLC)
FDA approved Epic Pharma, LLC's supplemental application for a generic combination product containing dextroamphetamine saccharate, amphetam…
-
FDA approval · 2015-04-17FDA Approved: DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE MONOHYDRATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE — Supplemental Application (Sandoz Inc)
FDA approved a supplemental application for a generic combination of dextroamphetamine and amphetamine salts (dextroamphetamine saccharate, …
-
FDA approval · 2015-04-17FDA Approved: DEXTROAMPHETAMINE SACCHARATE AND AMPHETAMINE ASPARTATE AND DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE — Supplemental Application (SpecGx LLC)
FDA approves a supplemental application from SpecGx LLC for a generic product containing four amphetamine/dextroamphetamine salt forms, enab…
-
FDA approval · 2015-04-17FDA Approved: EVEKEO — Supplemental Application (Azurity Pharmaceuticals, Inc.)
The FDA approved a supplemental application for EVEKEO (amphetamine sulfate) submitted by Azurity Pharmaceuticals, Inc., under ANDA200166. T…
-
FDA approval · 2015-04-14FDA Approved: METHYLPHENIDATE TRANSDERMAL SYSTEM — Supplemental Application (PADAGIS US LLC)
FDA approved a supplemental application for the Methylphenidate Transdermal System from PADAGIS US LLC, signaling regulatory approval for a …
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
FDA approval · 2015-04-03FDA Approved: DEXTROAMPHETAMINE SULFATE — Supplemental Application (Actavis Pharma, Inc.)
The FDA approved a supplemental application for dextroamphetamine sulfate from Actavis Pharma, Inc. under an ANDA.
-
FDA approval · 2015-03-20FDA Approved: METHYLPHENIDATE HYDROCHLORIDE — Supplemental Application (SpecGx LLC)
The FDA approved a supplemental application for methylphenidate hydrochloride submitted by SpecGx LLC. This action updates the product via a…
-
FDA approval · 2015-03-18FDA Approved: INTUNIV — Supplemental Application (Takeda Pharmaceuticals America, Inc.)
The FDA approved a supplemental application for INTUNIV (guanfacine) submitted by Takeda Pharmaceuticals America, Inc.
-
FDA approval · 2015-03-03FDA Approved: DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE, AND AMPHETAMINE SULFATE — Supplemental Application (Prasco Laboratories)
FDA approved a supplemental application from Prasco Laboratories for a generic product containing four amphetamine salts (dextroamphetamine …
-
FDA approval · 2015-03-02FDA Approved: DEXTROAMPHETAMINE SULFATE EXTENDED-RELEASE — Supplemental Application (SpecGx LLC)
The FDA granted approval of a supplemental application for dextroamphetamine sulfate extended-release from SpecGx LLC, updating the regulato…
-
FDA approval · 2015-02-25FDA Approved: METHYLPHENIDATE HYDROCHLORIDE — Original Application (Lupin Pharmaceuticals,Inc.)
The FDA approved Lupin Pharmaceuticals' methylphenidate hydrochloride generic through an Original Application (ANDA 204115).
-
FDA approval · 2015-02-04FDA Approved: DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE MONOHYDRATE, DEXTROAMPHETAMINE SULFATE, AMPHETAMINE SULFATE — Supplemental Application (Actavis Pharma, Inc.)
FDA approved a supplemental application for a generic product containing four amphetamine salt components. The approval supports use for att…
-
FDA approval · 2015-02-04FDA Approved: DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE — Supplemental Application (Epic Pharma, LLC)
FDA approved a supplemental application for a generic combination of amphetamine salts (dextroamphetamine saccharate, amphetamine aspartate,…
-
FDA approval · 2015-01-30FDA Approved: VYVANSE — Supplemental Application (Takeda Pharmaceuticals America, Inc.)
FDA approved a supplemental application for Vyvanse (lisdexamfetamine dimesylate) submitted by Takeda Pharmaceuticals America, Inc.
-
FDA approval · 2015-01-29FDA Approved: DEXTROAMPHETAMINE SULFATE — Supplemental Application (Teva Pharmaceuticals USA, Inc.)
The FDA approved a supplemental application for dextroamphetamine sulfate by Teva Pharmaceuticals USA, Inc. This action represents an approv…
-
FDA approval · 2015-01-29FDA Approved: DEXTROAMPHETAMINE SULFATE — Supplemental Application (SpecGx LLC)
FDA approved a supplemental application for dextroamphetamine sulfate from SpecGx LLC under an Abbreviated New Drug Application.
-
FDA approval · 2015-01-29FDA Approved: DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE MONOHYDRATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE — Supplemental Application (Sandoz Inc)
FDA approved a supplemental application from Sandoz Inc for a generic mixed amphetamine salt product containing dextroamphetamine and amphet…
-
FDA approval · 2015-01-29FDA Approved: DEXTROAMPHETAMINE SACCHARATE AND AMPHETAMINE ASPARTATE AND DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE — Supplemental Application (SpecGx LLC)
FDA approved a supplemental ANDA for a generic fixed-dose combination of dextroamphetamine and amphetamine salts (dextroamphetamine sacchara…
-
FDA approval · 2015-01-15FDA Approved: DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE, AND AMPHETAMINE SULFATE — Supplemental Application (Sun Pharmaceutical Industries, Inc.)
FDA approved Sun Pharmaceutical's supplemental application for a generic product containing the four amphetamine salt components (mixed amph…
-
FDA approval · 2014-11-19FDA Approved: INTUNIV — Supplemental Application (Takeda Pharmaceuticals America, Inc.)
The FDA approved a supplemental application for Intuniv (guanfacine) from Takeda Pharmaceuticals America, expanding the labeling for its use…
-
FDA approval · 2014-11-10FDA Approved: GUANFACINE — Supplemental Application (Actavis Pharma, Inc.)
The FDA approved Actavis Pharma, Inc.'s supplemental application for guanfacine, enabling the generic product to enter the market.
-
FDA approval · 2014-11-03FDA Approved: DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE — Supplemental Application (Epic Pharma, LLC)
FDA approved a supplemental application for a generic fixed-dose combination of dextroamphetamine and amphetamine salts manufactured by Epic…
-
FDA approval · 2014-10-15FDA Approved: METHYLPHENIDATE HYDROCHLORIDE (LA) — Original Application (Teva Pharmaceuticals USA, Inc.)
FDA approved an original application for methylphenidate hydrochloride (long-acting) generic product by Teva Pharmaceuticals USA, Inc. for t…
-
FDA approval · 2014-09-15FDA Approved: METHYLIN — Supplemental Application (SHIONOGI INC.)
FDA approved a supplemental application for METHYLIN (methylphenidate hydrochloride) submitted by Shionogi Inc.
-
FDA approval · 2014-09-12FDA Approved: EVEKEO — Supplemental Application (Azurity Pharmaceuticals, Inc.)
The FDA approved a supplemental application for EVEKEO (amphetamine sulfate) from Azurity Pharmaceuticals, Inc., resulting in an updated lab…